GA
CRSP icon

Guerra Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Guerra Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$65 Buy
+1
New +$57 ﹤0.01% 891

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Guerra Advisors's CRSP Position: Q3 2025 in Review

Guerra Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q3 2025: 1 share worth $65. The stake represents ﹤0.01% of the portfolio and ranks #891 among its holdings.

440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

  • Guerra Advisors held 1 share of CRISPR Therapeutics worth $65 as of Q3 2025.
  • CRISPR Therapeutics was a new Guerra Advisors position in Q3 2025.
  • CRISPR Therapeutics made up ﹤0.01% of Guerra Advisors's portfolio in Q3 2025, its #891 holding.
  • 440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Guerra Advisors's 13F filing for Q3 2025, filed 4 Nov 2025.